Navigation Links
Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
Date:9/30/2009

    Powerful effects seen in all subjects including those with low HDL -
    representing a majority of myocardial infarct patients

    TSX Exchange Symbol: RVX

CALGARY, Sept. 29 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that results from the Company's Phase 1b/2a clinical trial have met and exceeded expectations by successfully concluding the drug, RVX-208, is safe and tolerable. Most importantly RVX-208 has met its primary endpoint to increase the production of plasma ApoA-I, the key cardioprotective protein in high-density lipoprotein (HDL), often referred to as "good" cholesterol. ApoA-I is generally endorsed as a key protective factor against atherosclerosis and cardiovascular disease with 40% of all first heart attack patients having low ApoA-I.

Resverlogix's Phase 1b/2a study tested RVX-208 for 28 days in three different dosing arms. The most pronounced results were demonstrated among those subjects with low HDL cholesterol levels. Low HDL is an important risk factor in coronary and cardiovascular disease patients. Resverlogix will continue to build upon its world leading position in development of novel small molecules that increase ApoA-l production and reverse cholesterol transport (RCT) markers in patients with high vascular risk profiles. RCT is a path by which cholesterol on the arterial wall is transported back to the liver by ApoA-I lipid complexes for excretion. Additional analysis was performed on other key RCT markers which achieved high levels of statistical significance. The Company has established a dosing range that it deems will be safe, well tolerated and effective for Phase 2 intravascular ultrasound (IVUS) development trials.

"The range of increase in ApoA-l production of all subjects, but in particular low HDL subjects over placebo demonstrated in this study is one of the most significant pieces of data for RVX-208. We have excee
'/>"/>

Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
2. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
3. Resverlogix Provides Quarterly Update
4. Resverlogix Board of Directors Update
5. Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
6. Resverlogix Announces Closing of Debt Redemption
7. Resverlogix Eliminates Sixty Percent of Remaining Debt
8. Resverlogix Issues a Management Statement
9. Resverlogix Board of Directors Update
10. Resverlogix Notice of Conference Call & Webcast
11. Jan Gray Joins Resverlogix Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
(Date:7/10/2014)... Understanding the need for better quality and ... gap that currently exists in this area, ChanTest has ... of validated ion channel and GPCR cell lines. ... ion channels control many critical physiological functions throughout the ... potential to treat a variety of human diseases. ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Robert Harman, DVM, ... Medicine company, is proud to announce the relaunch of his ... with a new series called “ What are Stem Cells ... an honest and straightforward foundation in the basics of stem ... decision on the right type of treatment when considering regenerative ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Senior ... institutions and professional associations, addressed the challenges of “Reducing ... Medical Device Industries” through strategic sourcing. Describing the partnership ... with the Supply Chain Management Institute ( SCMI) ... event on June 24 at the Kroc Institute of ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
... Nev., Sept. 30, 2011 Lifeline Biotechnologies, Inc. (Pink Sheets: ... efforts to reestablish DTC services. Jim Holmes, Lifeline,s ... services to the Company we have not been successful.  We ... The value of Lifeline is not reflected in ...
... , SALT LAKE CITY, Sept. 29, 2011 University of ... catalysts, which are substances that speed chemical reactions and are ... the new method, the chemists also made a discovery that ... discovery: the sizes and electronic properties of catalysts interact to ...
... BioSpace , the leading life sciences employment and ... marking the 14th edition. (Logo: http://photos.prnewswire.com/prnh/20040907/CLTU006LOGO) ... Each company,s brand is added to an electronic and ... as well as at industry events and career fairs. ...
Cached Biology Technology:Lifeline Biotechnologies and Depository Trust Company 2Building better catalysts 2Building better catalysts 3BioSpace Spotlights Southern California's Life Science Community 2
(Date:7/11/2014)... new report from the Wildlife Conservation Society shows ... help economically valuable species such as lobster, conch, ... help re-colonize nearby reef areas. , The reporttitled ... systematic review of research literature from no-take areas ... Dr. Craig Dahlgren, a recognized expert in marine ...
(Date:7/11/2014)... were many fires burning in eastern New South Wales, ... 11. , At 03:35 UTC on July 11 (12:35 ... Aqua passed over eastern New South Wales (NSW), the ... visible image of the region and spotted smoke (light ... MODIS,s thermal bands, are outlined in red. , The ...
(Date:7/11/2014)... and Mineral Research awarded Michael F. Holick, PhD, MD, ... 2014 Louis V. Avioli Award. Holick, a professor of ... for revolutionizing the understanding of vitamin D and its ... a member of the American Society for Bone and ... mineral basic research. It is named for ASBMR,s first ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2
... from the Buck Institute for Age Research offers a ... neurodegenerative disorder which afflicts 24 million people worldwide. ... a protein implicated in AD, scientists in California and ... a new therapeutic target for the disease. The finding ...
... fish do it. But Prof. Yossi Loya from Tel Aviv ... to discover that Japanese sea corals engage in "sex switching" ... survival of fragile sea corals ― essential to all life ... In times of stress like extreme hot spells, the ...
... group of scientists is renewing calls for policymakers to ... eutrophication or nutrient pollution problems in fresh ... Science , the researchers argue that dual-nutrient reduction ... complex interactions between nitrogen and phosphorus in fresh and ...
Cached Biology News:A revolutionary new model for Alzheimer's disease 2Changing sexes on the sea floor 2
... Andrew J. Davison and ... • Contents include: information ... viruses, paramyxoviruses, influenza and ... covers analysis of viral ...
... U. Desselberger (1995) • This book ... together classical and molecular techniques currently ... infections and analysis of virus-specific antibodies ... are presented covering immunoassays, blotting and ...
...
... provide rapid and efficient removal of short ... salts from PCR products (Figure 1). The ... Binding Buffer options for fragments >100 bp ... in either single column or 96-well plate ...
Biology Products: